Non Detection of HIV-1 Proviral DNA in PBMCs of the Neonates Born to Iranian HIV-infected Mothers in PMTCT Program

AUTHORS

Zahra Habib 1 , Farah Bokharaei-Salim 1 , * , Seyed Jalal Kiani 1 , Saba Garshasbi 2 , Saeed Kalantari 3 , Khadijeh Khanaliha 4 , Sedigheh Taghinezhad-S 5 , Seyed Hamidreza Monavari 1 , Angila Ataei Pirkooh 1 , Maryam Esghaei 1

1 Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

2 Vice Chancellor for Health, Iran University of Medical Sciences, Tehran, Iran

3 Departments of Infectious Diseases and Tropical Medicine, Iran University of Medical Sciences, Tehran, Iran

4 Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran

5 Department of Microbiology, Faculty of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran

How to Cite: Habib Z , Bokharaei-Salim F, Kiani S J , Garshasbi S , Kalantari S, et al. Non Detection of HIV-1 Proviral DNA in PBMCs of the Neonates Born to Iranian HIV-infected Mothers in PMTCT Program, Arch Pediatr Infect Dis. Online ahead of Print ; In Press(In Press):e105098. doi: 10.5812/pedinfect.105098.

ARTICLE INFORMATION

Archives of Pediatric Infectious Diseases: In Press (In Press); e105098
Published Online: January 19, 2021
Article Type: Research Article
Received: May 26, 2020
Revised: November 11, 2020
Accepted: November 24, 2020
Uncorrected Proof scheduled for 9 (2)
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Background: Early diagnosis of immunodeficiency virus-1 infection in children and access to treatment for this infection is critical in decreasing infant mortality.

Objectives: The aim of the current survey was to determine the presence of HIV-1 genomic RNA in plasma and proviral DNA in peripheral blood mononuclear cell (PBMC) specimens of neonates born to HIV-infected mothers.

Methods: From March 2014 to February 2018, 73 neonates born to HIV-1-infected mothers covered by the prevention of mother-to-child transmission (PMTCT) program were enrolled in this study to compare two different diagnostic methods. After the extraction of viral RNA of plasma and genomic DNA of PBMC specimens, HIV-1 RNA and proviral DNA was tested by amplification of the long terminal repeat (LTR) region of HIV-1 using real-time PCR.

Results: Out of 73 evaluated infants, 41 infants (56.2%) were male. The average age of the mothers with HIV-1 infection was 30.7 ± 5.2 (range: 19–47) years. The results revealed that none of the infants were infected with HIV-1, and also all were negative for HIV-1 genomic RNA in plasma specimen and proviral DNA of HIV-1 in PMBC samples. During the present study, 20 infants born to HIV-1 positive mothers who were not included in the PMTCT project were accidentally identified. Four infants (20%) out of these 20 infants were infected with HIV, all were infected with CRF35-AD of HIV, and none carried variants with surveillance drug-resistant mutations.

Conclusions: The results of the present study showed that two molecular methods of detecting HIV infection (presence of genomic RNA of HIV-1 in plasma and proviral DNA of HIV-1 in PBMC specimens) are completely in agreement with each other, and the PMTCT program is possibly an effective program.

1. Background

Mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) infection is the most important cause of HIV-1 infection among children under the age of 15, especially in the first two years of life (1); therefore, there is a need for urgent planning to address the situation of these children (2). Moreover, early diagnosis of HIV infection in young children is crucial for making decisions about medical and social care (3). Recent studies on the management and treatment of HIV-infected infants have revealed that antiretroviral therapy (ART) should be implemented in the first three months of life (4, 5). The initial diagnosis of HIV infection is one of the most important issues in the prevention and treatment process of this infection (6), which can be achieved by screening infants for this infection. Accessibility, however, can be a very restrictive factor because serological tests in newborns cannot be used due to maternal antibody stability up to the age of 18 months (7). Therefore, the diagnosis of HIV infection in infants is based on other tests (7); for example, the viral culture, detection of p24 antigenemia, and determination of the presence of the virus genome in the patient’s samples (8).

The following restrictions have led to the use of molecular techniques to diagnose HIV infection in infants: specific biosafety equipment is needed for viral culture; it is very time-consuming, and its sensitivity is not high (9). Additionally, the sensitivity of P24 antigen (P24 Ag) detection is lower than that of molecular assays (10), and also, this P24 Ag may pass through the placenta and be detected in non-infected HIV newborns (11).

The presence of HIV nucleic acid (RNA in plasma or DNA in peripheral blood mononuclear cell [PBMC] samples) can be detected in the specimens with molecular techniques, and they can be qualitative or quantitative (12). These methods are now widely used all over the world (13). Thus, the necessity of the use of molecular biology techniques to diagnose HIV infection in HIV-positive neonates and infants under 18 months of age should be considered (14). Although in most cases, the antibody-antigen enzyme-linked immunosorbent assay test, HIV-1 RNA detection in plasma specimens, and western blot assay are the mainstay of clinical diagnosis (15), in several studies on HIV-exposed seronegative individuals (HESN) proviral DNA of HIV-1 has been diagnosed in PBMC samples using polymerase chain reaction (PCR). The seronegative infection has been reported in health care personnel accidentally exposed to infected blood, in people who have frequent blood transfusions, sexual partners of HIV-infected people, and also in children of HIV-1 positive mothers (1, 16).

According to the Joint United Nations Program on HIV/AIDS (UNAIDS) and World Health Organization (WHO), at the end of 2005, there were more than 2.3 million children under the age of 15 years infected by HIV, and annually 0.57 million HIV-1-infected children die (17).

According to a global estimate by WHO in 2016, about 36.7 million people were living with HIV infection (Africa: 25.6 million, South-East Asia: 3.5 million, USA: 3.3 million, Europe: 2.4 million, Western Pacific: 1.5 million, and the Eastern Mediterranean: 360,000) (http://www.who.int/hiv/data/en/). In 2016, the number of children (less than 15 years of age) living with HIV infection was approximately 2.1 million, the number of children (less than 15 years of age) newly infected with this virus was about 160,000 million (100,000 - 220,000), and the number of children (less than 15 years of age) who died of AIDS was about 120,000 million (79,000 - 160,000). In addition, about 872,500 million children (less than 15 years of age) received antiretroviral therapy (ART) from 2000 to 2015 worldwide (http://www.who.int/hiv/data/en/).

Most of the neonatal infections that are acquired at the time of delivery, as well as the in-utero viral infections, can be detected through existing tests, but in other cases, the virus remains inactive in the immune cell’s genome for a long time (2). In these children, there are no symptoms related to HIV/AIDS, whereas they never received antiretroviral treatment. Serological tests, viral load (HIV-1 RNA concentration) on plasma samples, and even in some cases, virus culture, are negative in pediatric samples (1).

When HIV infection is not diagnosed early, then without treatment, about half of HIV-positive infants would die before two years of age, and 75% would die within five years of age. These deaths can be prevented by early infant diagnosis (EID), effective care, and ART (18).

Studies have indicated that HIV DNA PCR is significantly more sensitive than co-culture in the detection of HIV-1 in infected infants, and this method is recommended as the gold standard for virologic diagnosis of HIV infection in infants (1, 19).

In Iran, according to the WHO guidelines, the neonates born to HIV-infected mothers have been screened for the detection of HIV-RNA in plasma using real-time PCR since 2014 (20).

2. Objectives

This study is the first study in Iran that evaluated the prevalence of HIV-1 infection in PBMC specimens of infants born to HIV-infected mothers using a DNA PCR assay.

3. Methods

3.1. Subjects

From March 2014 to February 2018, 73 consecutive Iranian infants born to HIV-1-infected mothers were studied in this current follow up study to compare two different diagnostic methods (20). All HIV positive mothers between the ages of 15 to 48 years old were considered eligible for the current research. It is noteworthy that the mothers of the neonates were entered into the prevention of mother-to-child transmission (PMTCT) project for HIV as per the Iranian guidelines (21), the criteria of which were as follows: (1) HIV-infected mothers received antiretroviral drugs; (2) all of them (HIV-infected mothers) had undergone cesarean section; (3) these mothers did not breastfeed their children; and also (4) newborns received zidovudine syrup (20).

Peripheral blood samples were taken from each neonate at two ages (4 - 6 weeks and 4 - 6 months), and HIV-1 infection was tested in plasma and PBMC samples (20). It should be noted that during the present study, 20 children who were born to HIV-1 infected mothers who were not included in the PMTCT project were accidentally found. The mothers of these children were unaware that they were infected with the virus and noticed that they were infected at the time of delivery or several months after the baby was born. The study was also conducted on the children. The current survey was approved by the Iran University of Medical Sciences (IUMS), Tehran, Iran’s local ethics committee, in accordance with the Helsinki Declaration (the ethical code: IR.IUMS.FMD.REC 1396.9411541002). The parents of the neonates were informed about the current investigation, and a written consent form was received from all of them before commencing the study.

3.2. Collection and Preparation of the Specimens

A peripheral blood sample of about 3 ml was taken from each neonate and placed in a vacutainer tube containing EDTA, and then the PBMCs of each specimen were isolated using a standard protocol by Ficoll Hypaque (Lympholyte-H, Cedarlane, Hornby, Canada). After washing the PBMCs with PBS (pH = 7.3 ± 0.1), 250 µL of RNA preservative solution) RNALater: Ambion, Austin, TX) was added to the cells. Afterward, they were kept at -80°C until use.

3.3. RNA Extraction and the HIV-1 Viral Load Determination

The viral RNA of the plasma samples was isolated by a QIAamp DSP Virus Kit (QIAGEN GmbH, Hilden, Germany), in accordance with the manufacturer’s protocols. The HIV-1 viral load level was determined using an Artus HIV-1 RG RT-PCR Kit (QIAGEN GmbH, Hilden, Germany), in accordance with the manufacturer’s guidelines.

3.4. Genomic DNA Extraction and the HIV-1 DNA Detection

Total DNA was isolated from PBMC specimen by a QIAamp® DNA Mini kit (Qiagen GmbH, Hilden, Germany), in accordance with the manufacturer’s protocol guidelines, and the concentration of total DNA was determined by a NanoDrop (Thermo Scientific, Wilmington, MA) spectrophotometer.

The proviral DNA of HIV-1 in the PBMC specimens was detected by the real-time PCR method using the Rotor-Gene Q (QIAGEN, Germany) system, as previously described in detail (22). Briefly, for amplification of the HIV-LTR region, a TaqMan probe (LTR-Probe), and a pair of primers (LTR-F, LTR-R2) that could amplify a conserved region of the HIV-LTR were used (22), and also as internal control, a TaqMan probe and a pair of primers that could amplify a conserved region of the human β-globin gene were used (22).

3.5. The Determination of HIV-1 Surveillance Drug-resistant Mutations (SDRMs)

Drug-resistance mutation of HIV-1 was determined using genotyping, as explained in detail in previous research (23). Sequences acquired from the HIV-1 positive specimens were aligned with the reference sequence of this virus (HXB2 [GenBank accession number: K03455]) using the CLC Main Workbench 5.5 (CLCbio, Boston, MA, USA) software. The list of SDRMs of the WHO was used to determine the presence of transmitted drug resistance mutations in the sequences obtained from the specimens (24). The MEGA software version 7.0.21 was used for the construction of a phylogenetic tree by the neighbor-joining method (Figure 1), using the obtained sequences (1015 bp) from the experiment, and the phylogenetic tree was evaluated by the bootstrap method (1,000 replicates).

Figure 1. The phylogenetic tree made based on the pol gene nucleotide sequences (1015 bp) of HIV-1 retrieved from plasma specimens of 4 HIV-1-infected infants and those corresponding to various complete genome sequences of HIV-1 obtained from the GenBank. Closed diamonds (♦) show CRF35-AD, closed triangles (▲) show subtype B, closed squares (■) show subtype D, opened diamonds (◊) show subtype A2, closed circles (●) show subtype A1, and closed inverse triangles (▼) show subtype CRF01-AE. The neighbor-joining technique was used for the construction of this phylogenetic. The bootstrap values equal to or greater than 70 obtained after 1000 replicates have been indicated in the figure.

3.6. Statistical Analysis

Statistical analysis of this assay was performed by SPSS version 20 (SPSS Inc., Chicago, IL, USA) software. The Kolmogorov-Smirnov test was used to assess the normality of the data. The statistical differences between categorical variables were determined by Fisher’s exact test or chi-square test, as appropriate. A P-value less than 0.05 (P < 0.05) was considered statistically significant.

4. Results

4.1. Characteristics of the Subjects

Seventy-three neonates born to Iranian HIV-infected mothers in the PMTCT project for HIV infection were enrolled in this study. Of the 73 studied infants, 41 (56.2%) were male, and the mean age of the HIV infected mothers was 30.7 ± 5.2 years (range: 19 - 47).

The demographic and epidemiological features, as well as laboratory data of the HIV-1 exposed infants and their parents, have been demonstrated in Table 1.

Table 1. Various Parameters Related to HIV-exposed Infants and Their Parents in Different Yearsa
Parameters YearsP-Value
201520162017
Characteristics of the Neonates Born to HIV-infected Mothers in PMTCT
Gender0.533
Male12 (63.2)15 (60.0)14 (48.3)
Female7 (36.8)10 (40.0)15 (51.7)
Characteristics of the HIV Infected Mothers in PMTCT
Age29.8 ± 5.5 (19 - 40)31.0 ± 5.2 (22 - 47)31.2 ± 5.3 (19 - 39)0.404
Age groups, y0.516
≤ 255 (26.3)4 (16.0)6 (20.7)
26 - 3410 (52.6)18 (72.0)15 (51.7)
≥ 354 (21.1)3 (12.0)8 (27.6)
CD4 count643.8 ± 282.1 (320 - 1483)494.4 ± 174.0 (135 - 859)662.1 ± 239.3 (310 - 1471)0.831
CD4 count categories0.520
≤ 3504 (21.1)5 (20.0)3 (10.3)
> 35015 (78.9)20 (80.0)26 (89.7)
Rout of infection0.090
Unprotected sex10 (52.6)16 (64.0)22 (75.9)
Intravenous drug user 0 (0.0)0 (0.0)2 (6.9)
Injection drug user sexual partner8 (42.1)5 (20.0)3 (10.3)
Tattooing0 (0.0)0 (0.0)1 (3.4)
Unknown1 (5.3)4 (16.0)1 (3.4)
Education0.502
Under diploma14 (73.7)19 (76.0)25 (86.2)
Diploma5 (26.3)6 (24.0)4 (13.8)
Characteristics of the Fathers
Rout of infection0.483
Intravenous drug user 7 (36.3)10 (40.0)11 (37.9)
Unprotected sex7 (36.8)2 (8.0)3 (10.3)
Unprotected sex and IDUs1 (5.3)4 (16.0)8 (27.6)
Unknown1 (5.3)2 (8.0)1 (3.4)
Education0.352
Under diploma18 (94.7)22 (88.0)21 (72.4)
Diploma0 (0.0)1 (4.0)5 (17.2)
Upper diploma0 (0.0)1 (4.0)1 (3.4)
Unknown1 (5.3)1 (4.0)2 (6.9)
HIV Infected Father0.761
No 3 (15.8)7 (28.0)6 (20.7)
Yes16 (84.2)17 (68.0)22 (75.9)
Unknown0 (0.0)1 (4.0)1 (3.4)

aValues are expressed as No. (%) or mean ± SD (range).

As shown in Table 1, there is no significant relationship between age, gender, CD4 count, HIV transmission pathway of parental infection, and parents’ education level with various years of the present study. However, it is worth noting that the route of HIV transmission of these mothers was largely through unprotected sex, and most of them were under the level of a high school diploma.

On the other hand, most of the HIV-infected fathers were injecting drug users, and their level of education was mostly under that of the high school diploma. It should be noted that 16 fathers were not infected with the virus. In this study, in PBMC specimens of the neonates born to HIV-infected mothers in the PMTCT project which HIV-1 RNA was not detected in their plasma samples, HIV-1 proviral DNA was also not detected.

It is worth mentioning that, in the current investigation, 20 HIV-infected women were accidentally found. None of these women were included in the PMTCT project, and their babies were born a few months previously. Of the 20 infants born to HIV-infected mothers, four children (20%) were infected with this virus. These four HIV-infected infants were tested for the presence of the proviral DNA of HIV-1, and the experiment found that all of them were positive for the presence of HIV-1 proviral DNA. Table 2 presents a comparison between the demographic, laboratory, and epidemiological characteristics of these infants and their mothers and their infection with HIV.

Table 2. Various Parameters Related to HIV-Exposed Neonates and Their Mothers Who Were not in PMTCT Project
HIV-infected InfantsHIV Negative InfantsTotalP-Value
Characteristics of the Neonates
No. (%)4 (20.0)16 (80.0)20 (100)
Male/female sex2/28/810/100.709
Characteristics of the Mothers
CD4 count ± SD (range)460.8 ± 379.0 (154 - 983)479.0 ± 211.0 (135 - 907)475.0 ± 240.0 (135 - 983)0.896
Age, y ± SD (range)31.0 ± 6.4 (25 - 40)30.4 ± 5.5 (19 - 38)30.5 ± 5.5 (19 - 40)0.846
Unprotected sex2 (50.0)8 (50.0)10 (50)1.000
Intravenous drug user sexual partner2 (50.0)7 (43.8)9 (45)1.000
Unknown0 (0.0)1 (6.3)1 (5)1.000
Education
Under diploma4 (100.0)11 (68.8)15 (75)0.530
Diploma0 (0.0)5 (31.3)5 (25)

4.2. Sequence Analysis of the PR-RT Gene Amplification

The phylogenetic analyses showed that all of the four HIV-1 positive children were infected by CRF35-AD, and none of them were infected with HIV-1 variants with SDRMs. The nucleotide sequences of the Pol region of HIV-1 reported in this study (four children with HIV-1 infection) were submitted to the GenBank database with the accession numbers from KY816748 to KY816750, and also MG944243.

5. Discussion

Progression of the disease after infection with HIV in infants is rapid; therefore, early detection and treatment of HIV-1 infection in children can dramatically reduce mortality rates (25). As some researchers believe that detecting the presence of HIV-1 proviral DNA is the gold standard for the diagnosis of this infection in neonates born to HIV-infected mothers (26, 27), we aimed at determining the presence of proviral DNA in PBMC samples of infants born to HIV-infected mothers. The obtained results of this study revealed that in PBMC samples of 73 infants born to HIV-positive mothers where their mothers and the infants had been previously entered into the PMTCT projects, and the genomic HIV-1 RNA was not detected in their plasma samples, no HIV-1 proviral DNA was detected. On the other hand, in this research, we accidentally found 20 infants born to mothers with HIV infection who had not been included in the PMTCT project. Four infants (20%) were infected with HIV, and none of them were infected with HIV-1 variants with surveillance drug-resistance mutations (SDRMs), and the HIV-1 proviral DNA was detected in PBMC samples of these four HIV-1-infected infants.

Several studies have indicated that HIV-1 proviral DNA detection in PBMC specimens is significantly effective in the diagnosis of HIV-1 infection in neonates and is suggested as the gold standard method for molecular diagnosis of HIV infection for this group (1, 28). The WHO recommended HIV-1 diagnosis for all HIV-exposed neonates (4 - 6 weeks of age) using molecular tests, as well as the initiation of ART, immediately after the diagnosis of HIV infection (29). Detection of HIV-1 proviral DNA in PBMC samples and HIV-1 RNA in plasma specimens have been used to diagnose HIV infection in infants (27).

Extracellular RNA of HIV may appear shortly after the infection, and HIV-1 RNA in plasma samples is detectable earlier and is more reliable than HIV-1 proviral DNA in PBMC specimens of neonates with perinatal infection (19, 30). Testing for HIV-1 RNA is more sensitive than the detection of HIV-1 proviral DNA for neonates younger than two months old, receiving prophylaxis with zidovudine syrup (8, 9). However, some reports do not show a difference between the results of these two molecular methods (29, 31). On the other hand, Burgard et al. (29) believed that the specificity of both HIV-1 proviral DNA and HIV-1 RNA PCR was 100% at all ages.

In Iran, the PMTCT project for HIV infection is currently in progress (20); therefore, the outcome of this project should be carefully evaluated. Fortunately, the results of our study revealed that the two molecular methods for the detection of HIV infection (genomic RNA of HIV-1 in plasma and proviral DNA of HIV-1 in PBMC specimens) are in perfect agreement with each other.

Regarding the results of this study, it can be concluded that all neonates who were born to HIV-infected mothers in the PMTCT project were completely negative for this infection (negative for both genomic RNA of HIV-1 in plasma and proviral DNA of HIV-1 in PBMC specimens), and the implementation of this project has prevented the transmission of this infection from mother to child, and consequently, this project has been very successful in Iran.

It has been reported that some individuals who are exposed to HIV repeatedly do not seroconvert. It seems that these people are resistant to being infected with this virus (1, 4). These individuals do not have any detectable anti-HIV-1 Abs in plasma; however, they have strong cell-mediated antiviral responses (9). There have also been rare reports of HIV-exposed seronegative persons with detected proviral DNA of HIV-1 in their PBMC samples (such as persons who have had sexual contact with HIV-infected partners, health care workers with accidental percutaneous exposure to HIV-infected samples, and also neonates born to HIV-1-positive mothers) (4).

In the case of pediatric infections, some infected infants (anti-HIV Ab-negative and HIV-1 proviral DNA-positive) seem to be able to eliminate virus-infected cells, whereas others can harbor HIV-1 proviral DNA in their cells for a long time (2). These children have been called ‘silent pediatric infections’. Fortunately, in the present study, all neonates born to HIV-1 positive mothers covered by the PMTCT project had genomic RNA of HIV-1 in plasma and also were negative for the proviral DNA of HIV-1 in PBMC specimens; therefore, none of them had silent pediatric infections.

It should be noted that in this research, 20 children were accidentally detected who were born to HIV-infected mothers and had not been covered by the PMTCT program, of whom four children (20%) were found infected with HIV. All these children had genomic RNA of HIV-1 in plasma and were also positive for proviral DNA of HIV-1 in their PBMC specimens. The results of the sequencing of the regions of HIV as well as the drug resistance test showed that these four HIV-1-positive neonates were infected with CRF35-AD, and it is noteworthy that none of them were infected with HIV-1 strains with SDRMs.

Also, the frequency of HIV-1 subtypes and CRFs in various HIV-infected populations in Iran is as follows: CRF35-AD: 88%; subtype B: 7.1%; CRF01-AE: 4.7% in individuals with sexually-transmitted infections with HIV (23); injection drug users infected with CRF35-AD: 100% (32); and individuals infected with CRF35-AD: 95.7% (33). A study on the frequency of HIV infection to determine the HIV subtypes or CRFs and also the presence of the SDRMs in Iranian infants born to HIV-positive mothers should be conducted.

5.1. Conclusions

Our results demonstrated that if HIV-infected pregnant women are recognized and included in the PMTCT project, not only will their children become HIV RNA-negative in their plasma, but also they will become HIV proviral DNA-negative in their cells. Therefore, with the full implementation of the PMTCT project, healthy infants will possibly be born to HIV-infected mothers.

Acknowledgements

Footnotes

References

  • 1.

    Palacios-Saucedo GC, Rivera-Morales LG, Vazquez-Guillen JM, Sanchez LM, Ramirez TJ, Briones E, et al. Drug resistance mutations during structured interruptions of HAART in two HIV-1-infected children. Curr HIV Res. 2011;9(3):154-9. doi: 10.2174/157016211795945250. [PubMed: 21457133].

  • 2.

    Bystryak S, Acharya C. Detection of HIV-1 p24 antigen in patients with varying degrees of viremia using an ELISA with a photochemical signal amplification system. Clin Chim Acta. 2016;456:128-36. doi: 10.1016/j.cca.2016.02.022. [PubMed: 26940950]. [PubMed Central: PMC4934021].

  • 3.

    World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO; 2016.

  • 4.

    Ton Q, Frenkel L. HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission. Curr HIV Res. 2013;11(2):126-36. doi: 10.2174/1570162x11311020005. [PubMed: 23432488].

  • 5.

    Lowick S, Sawry S, Meyers T. Neurodevelopmental delay among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa. Psychol Health Med. 2012;17(5):599-610. doi: 10.1080/13548506.2011.648201. [PubMed: 22313239].

  • 6.

    Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316(2):191-210. doi: 10.1001/jama.2016.8900. [PubMed: 27404187]. [PubMed Central: PMC5012643].

  • 7.

    Abdollahi A, Saffar H. The diagnosis of HIV infection in infants and children. Iran J Pathol. 2016;11(2):89.

  • 8.

    Kim EY, Stanton J, Korber BT, Krebs K, Bogdan D, Kunstman K, et al. Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based bio-barcode-amplification method. Nanomedicine (Lond). 2008;3(3):293-303. doi: 10.2217/17435889.3.3.293. [PubMed: 18510425]. [PubMed Central: PMC2821699].

  • 9.

    Bisoffi M, Severns V, Branch DW, Edwards TL, Larson RS. Rapid detection of human immunodeficiency virus types 1 and 2 by use of an improved piezoelectric biosensor. J Clin Microbiol. 2013;51(6):1685-91. doi: 10.1128/JCM.03041-12. [PubMed: 23515541]. [PubMed Central: PMC3716090].

  • 10.

    Biancotto A, Brichacek B, Chen SS, Fitzgerald W, Lisco A, Vanpouille C, et al. A highly sensitive and dynamic immunofluorescent cytometric bead assay for the detection of HIV-1 p24. J Virol Methods. 2009;157(1):98-101. doi: 10.1016/j.jviromet.2008.11.013. [PubMed: 19100289]. [PubMed Central: PMC4154487].

  • 11.

    Rich KC, Janda W, Kalish LA, Lew J, Hofheinz D, Landesman S, et al. Immune complex-dissociated p24 antigen in congenital or perinatal HIV infection: role in the diagnosis and assessment of risk of infection in infants. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(3):198-203. doi: 10.1097/00042560-199707010-00003. [PubMed: 9257654].

  • 12.

    Jagodzinski LL, Manak MM, Hack HR, Liu Y, Malia JA, Freeman J, et al. Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test. J Clin Microbiol. 2019;57(5). doi: 10.1128/JCM.01922-18. [PubMed: 30842229]. [PubMed Central: PMC6498003].

  • 13.

    Garrido C, Zahonero N, Corral A, Arredondo M, Soriano V, de Mendoza C. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol. 2009;47(4):1031-6. doi: 10.1128/JCM.02099-08. [PubMed: 19193847]. [PubMed Central: PMC2668340].

  • 14.

    Frizzera Dias C, Moreira-Silva SF, Reis MA, Ribeiro Patricio L, Biancardi Gavioli CF, Miranda AE. Late diagnosis and HIV infection in children attending a service of specialized care for pediatric AIDS in Brazil. Rev Soc Bras Med Trop. 2014;47(1):93-6. doi: 10.1590/0037-8682-1737-2013. [PubMed: 24749159].

  • 15.

    Gray ER, Bain R, Varsaneux O, Peeling RW, Stevens MM, McKendry RA. p24 revisited: a landscape review of antigen detection for early HIV diagnosis. AIDS. 2018;32(15):2089-102. doi: 10.1097/QAD.0000000000001982. [PubMed: 30102659]. [PubMed Central: PMC6139023].

  • 16.

    Ortega PAS, Saulle I, Mercurio V, Ibba SV, Lori EM, Fenizia C, et al. Interleukin 21 (IL-21)/microRNA-29 (miR-29) axis is associated with natural resistance to HIV-1 infection. AIDS. 2018;32(17):2453-61. doi: 10.1097/QAD.0000000000001938. [PubMed: 30005016].

  • 17.

    Montoya CJ, Toro MF, Aguirre C, Bustamante A, Hernandez M, Arango LP, et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem Inst Oswaldo Cruz. 2007;102(4):501-8. doi: 10.1590/s0074-02762007005000055. [PubMed: 17612772].

  • 18.

    Fonjungo PN, Girma M, Melaku Z, Mekonen T, Tanuri A, Hailegiorgis B, et al. Field expansion of DNA polymerase chain reaction for early infant diagnosis of HIV-1: The Ethiopian experience. Afr J Lab Med. 2013;2(1):31. doi: 10.4102/ajlm.v2i1.31. [PubMed: 26855901]. [PubMed Central: PMC4740918].

  • 19.

    Fiscus SA, McMillion T, Nelson JA, Miller WC. Validation of the Gen-Probe Aptima qualitative HIV-1 RNA assay for diagnosis of human immunodeficiency virus infection in infants. J Clin Microbiol. 2013;51(12):4137-40. doi: 10.1128/JCM.01525-13. [PubMed: 24088864]. [PubMed Central: PMC3838099].

  • 20.

    Bokharaei-Salim F, Kalantari S, Gholamypour Z, Najafi A, Keyvani H, Esghaei M, et al. Investigation of the effects of a prevention of mother-to-child HIV transmission program among Iranian neonates. Arch Virol. 2018;163(5):1179-85. doi: 10.1007/s00705-017-3661-1. [PubMed: 29383588].

  • 21.

    World Health Organization. Global report: UNAIDS report on the global AIDS epidemic. Geneva: WHO; 2016.

  • 22.

    Jarchi M, Bokharaei-Salim F, Esghaei M, Kiani SJ, Jahanbakhsh F, Monavari SH, et al. The Frequency of HIV-1 Infection in Iranian Children and Determination of the Transmitted Drug Resistance in Treatment-Naive Children. Curr HIV Res. 2019;17(6):397-407. doi: 10.2174/1570162X17666191106111211. [PubMed: 31702525].

  • 23.

    Vahabpour R, Bokharaei-Salim F, Kalantari S, Garshasbi S, Monavari SH, Esghaei M, et al. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Arch Virol. 2017;162(6):1477-85. doi: 10.1007/s00705-017-3228-1. [PubMed: 28181034].

  • 24.

    Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3). e4724. doi: 10.1371/journal.pone.0004724. [PubMed: 19266092]. [PubMed Central: PMC2648874].

  • 25.

    Boyle DS, Lehman DA, Lillis L, Peterson D, Singhal M, Armes N, et al. Rapid detection of HIV-1 proviral DNA for early infant diagnosis using recombinase polymerase amplification. mBio. 2013;4(2). doi: 10.1128/mBio.00135-13. [PubMed: 23549916]. [PubMed Central: PMC3622927].

  • 26.

    Nicastri E, Palmisano L, Sarmati L, D'Ettorre G, Parisi S, Andreotti M, et al. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens. Curr HIV Res. 2008;6(3):261-6. doi: 10.2174/157016208784325010. [PubMed: 18473790].

  • 27.

    Mamadou D, Yu-Huang Z, Xia C, Bo H, Hua-Ying Z, Yan H, et al. HIV DNA and immune alteration during successful HAART. Curr HIV Res. 2013;11(4):255-62. doi: 10.2174/1570162x113119990041. [PubMed: 23822818].

  • 28.

    Lakshmi V, Sudha T, Dandona R, Kumar GA, Dandona L. Application of Polymerase Chain Reaction to Detect HIV-1 DNA in Pools of Dried Blood Spots. Indian J Microbiol. 2011;51(2):147-52. doi: 10.1007/s12088-011-0135-0. [PubMed: 22654156]. [PubMed Central: PMC3209897].

  • 29.

    Burgard M, Blanche S, Jasseron C, Descamps P, Allemon MC, Ciraru-Vigneron N, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr. 2012;160(1):60-6 e1. doi: 10.1016/j.jpeds.2011.06.053. [PubMed: 21868029].

  • 30.

    Steketee RW, Abrams EJ, Thea DM, Brown TM, Lambert G, Orloff S, et al. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. New York City Perinatal HIV Transmission Collaborative Study. J Infect Dis. 1997;175(3):707-11. doi: 10.1093/infdis/175.3.707. [PubMed: 9041350].

  • 31.

    Roques PA, Gras G, Parnet-Mathieu F, Mabondzo AM, Dollfus C, Narwa R, et al. Clearance of HIV infection in 12 perinatally infected children: clinical, virological and immunological data. AIDS. 1995;9(12):F19-26. [PubMed: 8605047].

  • 32.

    Memarnejadian A, Menbari S, Mansouri SA, Sadeghi L, Vahabpour R, Aghasadeghi MR, et al. Transmitted Drug Resistance Mutations in Antiretroviral-Naive Injection Drug Users with Chronic HIV-1 Infection in Iran. PLoS One. 2015;10(5). e0126955. doi: 10.1371/journal.pone.0126955. [PubMed: 25962088]. [PubMed Central: PMC4427455].

  • 33.

    Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, et al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PLoS One. 2013;8(4). e61864. doi: 10.1371/journal.pone.0061864. [PubMed: 23626742]. [PubMed Central: PMC3633940].

  • Copyright © 2021, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
    COMMENTS

    LEAVE A COMMENT HERE: